Beneficial influence of postmenopausal estrogen therapy on serum adhesion molecules is independent of the route and dose of administration.
ABSTRACT In current literature, the immune-inflammatory theory of atherosclerosis is widely discussed. The role of how adhesion molecules contribute to the development of atheromatic plaques is especially underlined.
120 females in menopausal age were included in the study between 2004 and 2009. All the women were of menopausal age (51±3 years), from southern Poland, with FSH levels above 30 mIU/ml, and complaining of menopausal symptoms that disturbed normal daily activity. The study was conducted over a 6 month period. Three groups of 40 randomized patients were selected. The control group consisted of 40 volunteers, who were also from southern Poland, in good health, without menopausal symptoms, or menstrual periods in the last 6 months. Control subjects were match according to age and weight, with FSH levels above 25 mIU/ml and normal TSH and prolactin values. All patients, in the treatment and control groups were seronegative for Chlamydia pneumonia throughout the duration of the study.
After 6 months, hormonal therapy was found to significantly reduce levels of sICAM-1 and sVCAM-1 in all treated groups compared to the control group and the results were statistically significant. Alternatively, in the latter group, we observed increased levels of the investigated adhesion molecules (group I: 37.5 µg/24h transdermal estradiol + dydrogesteron; group II 50 µg/24h transdermal estradiol + medroxyprogesteron; group III 1mg of oral estradiol + noretisteron sICAM-1 and control group; using paired Wilcoxon test).
All of the investigated estrogen therapy schemas have a favorable impact on the blood levels of sICAM-1 and sVCAM-1 in postmenopausal women without cardiovascular risk factors, reducing their concentration.
- SourceAvailable from: Suzanne C Ho[Show abstract] [Hide abstract]
ABSTRACT: BACKGROUND:: Despite data from animal models and observational studies that are generally supportive for the soy/isoflavones lowering blood pressure (BP) and improving vascular function, the current findings from clinical trials are still inconclusive. OBJECTIVES:: To examine whether soy protein with isoflavones or isoflavones alone reduce BP and endothelial cytokines, and whether the effects differed by baseline BP level. METHODS:: A double-blind randomized, placebo-controlled trial was conducted among 180 postmenopausal Chinese women with mild hyperglycemia. Participants were randomly assigned to one of the three arms to receive either 15 g soy protein and 100 mg isoflavones (Soy group), or 15 g milk protein and 100 mg isoflavones (Iso group), or 15 g milk protein (placebo group) on a daily basis for 6 months. RESULTS:: No significant difference was observed in the change and %change of BP and endothelial cytokine levels among the three study groups. However, a subgroup analysis among 130 pre and hypertensive women suggested that soy protein and isoflavones significantly reduced SBP [-4.25%, 95% confidence interval (CI) -7.9 to -0.6%, P = 0.02] and the level of soluble intercellular adhesion molecule (sICAM)-1 (-22.6%, 95% CI -42.8 to -2.3%, P = 0.02) relative to milk protein after 6-month intervention. CONCLUSIONS:: Our 6-month randomized controlled trial in prediabetic postmenopausal women indicated that soy protein and isoflavones had no significant effect on BP and endothelial molecules; however, a favorable reduction on SBP, sICAM-1 and E-selectin was observed among women with initial elevated BP.Journal of Hypertension 11/2012; · 4.22 Impact Factor